The Ministry of Health of Russia approved a single dose administration and extended the indications for use of the «Convacell» vaccine for adult people aged 60 and older. Within the clinical studies it has been proved that the immunity to the virus SARS-CoV-2 after the immunization with «Convacell» persists during more than a year.
The administration of the «Convacell» vaccine activates innate and adaptive cellular immunity. The infected cells are eliminated from the organism by using direct and antibody-dependent cytotoxicity. The vaccine does not contain the virus or its parts, so it cannot provoke a disease.
The level of humoral immunity after the vaccination with «Convacell» can be evaluated by the available antigen tests to N protein. The full information is represented on the web page Convacell.ru.
We recall that the particularity of the new vaccine is the presence in it of the recombinant nucleocapsid protein of the virus, which almost does not change when new strains of SARS-CoV-2 appear. The «Convacell» vaccine is developed and manufactured by the St. Petersburg Institute of Vaccines and Serums of the FMBA of Russia. The product was launched to the market in September of 2022.